$96.85
1.48%
Nasdaq, Oct 01, 04:02 pm EDT. Closed.
ISIN
US09075V1026
Symbol
BNTX

BioNTech SE - ADR Target price 2026 - Analyst rating & recommendation

BioNTech SE - ADR Classifications & Recommendation

Buy
78%
Hold
22%

BioNTech SE - ADR Price Target

Target Price $131.07
Price $96.85
Potential
Number of Estimates 24
24 Analysts have issued a price target BioNTech SE - ADR 2027 . The average BioNTech SE - ADR target price is $131.07. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 27 analysts: 21 Analysts recommend BioNTech SE - ADR to buy, 6 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the BioNTech SE - ADR stock has an average upside potential 2027 of . Most analysts recommend the BioNTech SE - ADR stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Billion $ 3.23 2.09
4.32% 35.82%
EBITDA Margin 5.82% -77.59%
178.75% 1,432.59%
Net Margin -39.59% -78.42%
63.70% 98.10%

24 Analysts have issued a sales forecast BioNTech SE - ADR 2026 . The average BioNTech SE - ADR sales estimate is

$2.1b
unlock
. This is
30.49% lower
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$2.6b 12.66%
unlock
, the lowest is
$1.8b 38.37%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $3.2b 4.32%
2026
$2.1b 35.82%
unlock
2027
$2.1b 0.33%
unlock
2028
$2.7b 31.10%
unlock
2029
$2.4b 13.29%
unlock
2030
$2.9b 22.04%
unlock
2031
$3.9b 34.16%
unlock
2032
$4.9b 26.66%
unlock
2033
$5.4b 9.59%
unlock

15 Analysts have issued an BioNTech SE - ADR EBITDA forecast 2026. The average BioNTech SE - ADR EBITDA estimate is

$-1.6b
unlock
. This is
227.79% lower
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-1.3b 174.74%
unlock
, the lowest is
$-1.9b 289.35%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $188m 182.15%
2026
$-1.6b 955.28%
unlock
2027
$-1.7b 5.06%
unlock
2028
$-1.2b 28.97%
unlock
2029
$-1.3b 7.87%
unlock
2030
$-500m 61.62%
unlock
2031
$389m 177.68%
unlock
2032
$1.1b 175.08%
unlock
2033
$1.4b 29.72%
unlock

EBITDA Margin

2025 5.82% 178.75%
2026
-77.59% 1,432.59%
unlock
2027
-81.78% 5.40%
unlock
2028
-44.31% 45.82%
unlock
2029
-55.12% 24.40%
unlock
2030
-17.34% 68.54%
unlock
2031
10.04% 157.90%
unlock
2032
21.80% 117.13%
unlock
2033
25.81% 18.39%
unlock

23 BioNTech SE - ADR Analysts have issued a net profit forecast 2026. The average BioNTech SE - ADR net profit estimate is

$-1.6b
unlock
. This is
14.34% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-1.0b 44.97%
unlock
, the lowest is
$-2.3b 21.26%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $-1.3b 70.77%
2026
$-1.6b 27.15%
unlock
2027
$-1.6b 0.61%
unlock
2028
$-1.3b 20.65%
unlock
2029
$-1.1b 11.92%
unlock
2030
$-795m 30.05%
unlock
2031
$79.3m 109.97%
unlock
2032
$633m 698.05%
unlock
2033
$1.1b 68.96%
unlock

Net Margin

2025 -39.59% 63.70%
2026
-78.42% 98.10%
unlock
2027
-78.20% 0.28%
unlock
2028
-47.33% 39.48%
unlock
2029
-48.08% 1.58%
unlock
2030
-27.56% 42.68%
unlock
2031
2.05% 107.44%
unlock
2032
12.90% 529.27%
unlock
2033
19.89% 54.19%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ -5.28 -6.52
69.77% 22.33%
P/E negative
EV/Sales 4.01

23 Analysts have issued a BioNTech SE - ADR forecast for earnings per share. The average BioNTech SE - ADR EPS is

$-6.52
unlock
. This is
13.53% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-4.15 44.52%
unlock
, the lowest is
$-9.15 22.33%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-5.28 69.77%
2026
$-6.52 22.33%
unlock
2027
$-6.48 0.61%
unlock
2028
$-5.14 20.68%
unlock
2029
$-4.53 11.87%
unlock
2030
$-3.17 30.02%
unlock
2031
$0.32 110.09%
unlock
2032
$2.52 687.50%
unlock
2033
$4.26 69.05%
unlock

P/E ratio

Current -13.04 77.80%
2026
-15.09 15.75%
unlock
2027
-15.18 0.60%
unlock
2028
-19.13 26.02%
unlock
2029
-21.72 13.54%
unlock
2030
-31.05 42.96%
unlock
2031
311.42 1,102.96%
unlock
2032
39.02 87.47%
unlock
2033
23.10 40.80%
unlock

Based on analysts' sales estimates for 2026, the BioNTech SE - ADR stock is valued at an EV/Sales of

and an P/S ratio of
11.86
unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.79 25.68%
2026
4.01 43.77%
unlock
2027
4.02 0.33%
unlock
2028
3.07 23.72%
unlock
2029
3.54 15.33%
unlock
2030
2.90 18.06%
unlock
2031
2.16 25.46%
unlock
2032
1.71 21.05%
unlock
2033
1.56 8.75%
unlock

P/S ratio

Current 8.25 17.84%
2026
11.86 43.87%
unlock
2027
11.90 0.33%
unlock
2028
9.08 23.72%
unlock
2029
10.47 15.33%
unlock
2030
8.58 18.06%
unlock
2031
6.40 25.46%
unlock
2032
5.05 21.05%
unlock
2033
4.61 8.75%
unlock

Current BioNTech SE - ADR Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
BMO Capital
Locked
➜
Locked
Locked Sep 08 2026
Canaccord Genuity
Locked
➜
Locked
Locked Aug 31 2026
Citigroup
Locked
➜
Locked
Locked Aug 05 2026
Evercore ISI Group
Locked
➜
Locked
Locked Aug 05 2026
Morgan Stanley
Locked
➜
Locked
Locked Jul 08 2026
UBS
Locked
➜
Locked
Locked May 27 2026
Bernstein
Locked
➜
Locked
Locked May 22 2026
Analyst Rating Date
Locked
BMO Capital:
Locked
➜
Locked
Sep 08 2026
Locked
Canaccord Genuity:
Locked
➜
Locked
Aug 31 2026
Locked
Citigroup:
Locked
➜
Locked
Aug 05 2026
Locked
Evercore ISI Group:
Locked
➜
Locked
Aug 05 2026
Locked
Morgan Stanley:
Locked
➜
Locked
Jul 08 2026
Locked
UBS:
Locked
➜
Locked
May 27 2026
Locked
Bernstein:
Locked
➜
Locked
May 22 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today